Loading stock data…
SION
$43.29+2.32 (+5.66%)
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sionna Therapeutics, Inc. in the Healthcare sector is trading at $43.29. The stock is currently near its 52-week high of $46.46, remaining 25.8% above its 200-day moving average. Technical signals show neutral RSI of 45 and bullish MACD crossover, explaining why SION maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$43.29
Potential Upside
5%
Whystock Fair Value$45.45
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$50.60+16.9%
Range$24.00 – $63.00
Fundamentals
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmemb...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.94B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-24.72%
Volume
Today's trading volume
311,280
Recent News
A Look At Sionna Therapeutics (SION) Valuation After Its Strong 1 Year Return And Premium P/B Ratio
What Sionna Therapeutics Stock Data Suggests Right Now Sionna Therapeutics (SION) has drawn investor attention after a very large 1 year total return of 216.26%, alongside mixed shorter term moves including a roughly flat month and a 9.06% decline over the past 3 months. See our latest analysis for Sionna Therapeutics. Recent trading shows momentum cooling, with a 1-year total shareholder return of 216.26% contrasted by a 90-day share price return of a 9.06% decline from the latest share...
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch
This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance.
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story
This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings.
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.